Janssen in Zug is the Swiss sales and marketing subsidiary of the research-based, global leader in the pharmaceutical industry. The company develops pharmaceutical preparations for pain relief, gynecology, neurology, psychiatry and virology. Janssen has developed over 80 drugs, five of which are included in the WHO list of the most important medications.
Johnson & Johnson and Janssen are deeply engrained in Switzerland. Janssen is the combination of Janssen –founded by Dr. Paul Janssen in Belgium in 1953, and acquired by Johnson & Johnson in 1961 and Cilag, acquired in 1959. Cilag was founded by Dr. Bernhard Joos in Switzerland in 1936. In 1994 Janssen and Cilag merged and since 2010 are operating under the Janssen brand name.
Contact
Janssen-Cilag AG
Gubelstrasse 34
CH-6300 Zug
tel +41 58 231 34 46
Urs Vögeli, managing director for Janssen Switzerland, outlines the importance of the Swiss operations to Janssen, his interesting career journey, Janssen’s commitment to bringing transformational medical innovations to Swiss patients,…
Europe accounts for a substantial share of Takeda’s business, hosts a significant slice of the company’s manufacturing footprint, and is involved in around half of its late-stage trials and priority…
Genmab is moving into one of the most consequential chapters in its history, as decades of antibody innovation converge with an ambition to take greater ownership of the journey from…
The debate around Europe’s pharmaceutical future is shifting beyond innovation alone towards the broader challenge of sustaining access, strengthening resilience and creating a more competitive operating environment. Arun Narayan outlines…
The priority should be to ensure that reimbursement systems can support sustainable healthcare budgets, timely patient access and continued pharmaceutical innovation Delivering the first approved treatment for metabolic dysfunction-associated steatohepatitis…
The European Commission has set itself an ambitious target: making Europe the world’s most attractive destination for life sciences by 2030. In recent conversations with PharmaBoardroom, executives leading Europe for…
The opportunity now is to ensure that the policy and access environment evolves at the same pace as the science Europe possesses one of the world’s strongest scientific ecosystems, yet…
Europe’s position as a global healthcare leader is being tested by intensifying competition from both the US and China. As CSL’s Dirk Hoheisel points out, this is not because Europe…
Whilst G7 countries have long been the traditional homes of pharmaceutical innovation, there is increased global competition, and a real risk that this longstanding leadership will be lost without concerted…
Nearly six years after becoming a standalone business, Merz Therapeutics is expanding beyond its neurotoxin heritage to build a broader specialty neurology platform across Europe and internationally. Newly appointed Region…
Europe stands at a critical moment as healthcare systems face growing pressure to accelerate patient access, adapt to more complex therapies, and remain competitive in a global innovation race increasingly…
Ophthalmology is a booming niche, with investment flowing in, M&A up, and a burgeoning cast of biotechs – including the three European leaders profiled below – vying for a share…
Natural remedies are on the rise. The USD 80 billion global natural health products market is projected to nearly double by 2033, according to Market Growth Reports, as patients with…
See our Cookie Privacy Policy Here
